Vaxart ends Q2 2026 with $64 million in cash
Vaxart reported favorable 12-month safety data from its COVID-19 vaccine trial with no vaccine-related serious complications.
The company received $29 million from BARDA to fund expanded safety and efficacy analyses.
Vaxart has $64 million in cash and short-term investments, enough to fund operations into Q2 2027.
The company is seeking a norovirus vaccine partner and has revised its board leadership and committee structures.